Shorter Antibiotic Course Safe, Effective for Uncomplicated Childhood CAP
The randomized, double-blind, placebo-controlled study included a total of 380 patients aged 6 to 71 months with nonsevere CAP.
The randomized, double-blind, placebo-controlled study included a total of 380 patients aged 6 to 71 months with nonsevere CAP.
The authors utilized medical and pharmacy claims obtained from the Optum Clinformatics Data Mart Database.
The most common presenting complaints included shortness of breath, rhinorrhea, and hoarseness.
The survey asked about the likelihood of both child and parental vaccination, perceptions about the vaccines and the level of trust in various sources of information.
Both treatment options were found to be effective for adults with allergic rhinitis or rhinoconjunctivitis.
After removal of the warning, cephalosporin use increased from 17.9% to 27.0% at the intervention site.
The recommended time interval between the 2 doses is 21 days for the Pfizer-BioNTech vaccine and 28 days for the Moderna vaccine; however, if a delay is unavoidable, 42 days between doses is considered permissible.
The authors described the cases of 3 patients with moderate to severe COVID-19 pneumonia who were treated with 2g of icosapent ethyl administered twice daily via a nasogastric tube.
The study, which was fully remote and contactless, aimed to evaluate whether early treatment with fluvoxamine reduced the likelihood of clinical deterioration and disease severity in patients with mild COVID-19 illness.
To estimate the association between attribute level and probability of choosing and receiving a vaccine, the study authors calculated the average marginal component effects sizes as well as marginal means.